NeoStem Announces Licensing of Patent Portfolio From The Rockefeller University Expanding Its Cancer Immunotherapy Intellectual Property Portfolio

NEW YORK, (GLOBE NEWSWIRE via COMTEX) NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, announced today that the Company has entered into an exclusive license agreement with The Rockefeller University for patented technologies that further expand the Company s intellectual property portfolio associated with its Targeted Cancer Immunotherapy Program. The discovery of dendritic cells in 1973, resulting in a 2011 Nobel Prize in Physiology or Medicine, bridged the two principal aspects of immunity (innate and adaptive) first defined by Nobel Prize recipients in Physiology or Medicine in 1908. It was subsequently proved that dendritic cells, part of the innate immune system, orchestrate the immune response to specific antigens by absorbing antigens and, when activated, present the specific antigens to B and T cells that result in antigen specific adaptive immunity. The Rockefeller University patents licensed by NeoStem are titled: Methods for use of Apoptotic
http://bit.ly/1pbO9ZL